TabCAT Assessment for Dementia

N/A

Recruiting

Led By Katherine Possin, PhD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Patients under the age of 18.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up during the 12-month steady state period

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a tablet tool to detect dementia in primary care. Results will assess its accuracy and effectiveness in helping spot cognitive impairment.

Who is the study for?

This trial is for adults who have visited one of the 26 participating primary care clinics in Southern California during the study period. It's focused on those aged 65 and older for the main analysis but includes adults over 18. Children under 18 cannot participate.

What is being tested?

The TabCAT Brain Health Assessment, a tablet-based tool designed to detect cognitive impairments including dementia, is being tested. The study aims to see if this user-friendly technology with automatic scoring improves detection rates in a real-world clinic setting.

What are the potential side effects?

Since this trial involves an assessment tool rather than medication or invasive procedures, traditional side effects are not applicable. However, participants may experience stress or discomfort while completing cognitive tests.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ during the 12-month steady state period

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~during the 12-month steady state period

This trial's timeline: 3 weeks for screening, Varies for treatment, and during the 12-month steady state period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

The rate of patients with at least one cognitive impairment diagnosis documented in the medical record by any primary care provider during the 12-month steady state period at the clinic.

Secondary study objectives

The rate of patients who have a documented standardized cognitive assessment performed in the primary care clinic within 4 months of an incident cognitive impairment diagnosis.

The rate of patients who have a referral to Geriatrics, Neurology or Psychiatry.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: TabCAT-Brain Health Assessment Clinical PathwayExperimental Treatment1 Intervention

Primary care providers concerned that their patients are exhibiting signs of cognitive decline based on patient, informant (family), or provider concerns will refer them for a TabCAT-BHA assessment and follow-up care.

Group II: Usual Care Clinical PathwayActive Control1 Intervention

Patients in the control practices will continue with usual care workflows.

0 / 1Eligibility criteria met